No, SPRAVATO is only approved for use in ages 18 or older.
No, SPRAVATO is not known to be safe for use in pregnancy or breastfeeding.
Twice a week for the first 4 weeks, followed by once a week. Our healthcare provider will determine your frequency after the first two months are completed. This will depend on your response. Prepare to be on-site for 2 hours each visit. Some patients will remain on Spravato as a part of their maintenance medication just as you would on an oral antidepressant.
As SPRAVATO may cause sedation and other side effects that may cause impairment of operating heavy machinery, you must pre-arrange for a ride after each visit. This includes rideshare or a trusted family member, caretaker or friend 18 years or older with a valid driver’s license. This will be your responsibility to ensure this individual meets this criteria.
Our office does complete short-term disability and intermittent leave (i.e . FMLA) paperwork. This is based on medical necessity and on a case-by-case basis. We cannot guarantee this will be approved as the decision will be determined by the third-party company who your employer uses.
Unlike other neuromodulation treatments such as TMS (transcranial magnetic stimulation), epilepsy or seizures is NOT a contraindication. You may likely be use Spravato. Our healthcare provider will determine this based on your medical history.
Most commonly patients report sleepiness (sedation) which is why you cannot drive yourself from the office. Some other side effects may include dizziness, fainting, spinning sensation, feeling disconnected from yourself or anxiety. Please review important safety information for more details.
In a short term clinical trial of adults with treatment-resistant depression, those who took Spravato and an oral antidepressant experienced a greater reduction in depressive symptoms at four weeks compared to those who received a placebo and an oral depressant.
In a long term study after 16 weeks of therapy, patients who stayed on Spravato were less likely to experience a return of depressive symptoms than those who stopped therapy.